InflaRx IFRX
NASDAQ IFRX
$2.05 -0.04 (-1.91%)
As of: Sep 10, 2026 · 3:59 PM EDT

InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026)

InflaRx's (IFRX) quarterly Total Non-Current Liabilities came in at $694361.3 in Q2 2026, up 154.79% year-over-year from $272525.0 in Q2 2025, and down 2.55% quarter-over-quarter from $712532.2 in Q1 2026.

Analysis

InflaRx (IFRX) Total Non-Current Liabilities (2016 - 2026) Analysis & Trends

InflaRx has disclosed Total Non-Current Liabilities across 11 years of filings, most recently posting $694361.3 for Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities rose 154.79% year-over-year to $694361.3; the TTM figure through Jun 2026 stood at $694361.3 (up 154.79% YoY), while the FY2025 annual figure was $765842.5, up 64.4% from the prior year.
  • Total Non-Current Liabilities came in at $694361.3 for Q2 2026 at InflaRx, down from $712532.2 in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.3 million in Q2 2022 to a low of $272525.0 in Q2 2025.
  • Average Total Non-Current Liabilities over 5 years is $805455.9, with a median of $835966.4 recorded in 2023.
  • Year-over-year, Total Non-Current Liabilities surged 446.31% in 2022 and sank 60.34% in 2025.
  • Over 5 years, Total Non-Current Liabilities stood at $1.0 million in 2022, then decreased by 19.42% to $842023.0 in 2023, then tumbled by 44.68% to $465846.7 in 2024, then soared by 69.38% to $789046.9 in 2025, then fell by 12.0% to $694361.3 in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $694361.3 in Q2 2026, $712532.2 in Q1 2026, and $789046.9 in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 81.11 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 36.04 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 5.92 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 7.74 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 40.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 3.92 Bn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 4.20 Bn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 12.42 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 378.37 Mn
10 InflaRx 139.29 Mn -44.96 Mn 2.74 Mn 694,361.26
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 694,361.26
Mar 31, 2026 712,532.19
Dec 31, 2025 789,046.90
Sep 30, 2025 861,618.15
Jun 30, 2025 272,524.95
Mar 31, 2025 349,563.29
Dec 31, 2024 465,846.68
Sep 30, 2024 588,431.50
Jun 30, 2024 687,131.81
Mar 31, 2024 829,909.78
Dec 31, 2023 842,023.04
Sep 30, 2023 880,333.32
Jun 30, 2023 927,150.52
Mar 31, 2023 1.00 Mn
Dec 31, 2022 1.04 Mn
Sep 30, 2022 1.13 Mn
Jun 30, 2022 1.29 Mn
Mar 31, 2022 1.13 Mn
Dec 31, 2021 1.26 Mn
Sep 30, 2021 1.40 Mn